Methods of treating Fabry patients having renal impairment
Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
1. A method of treating Fabry disease, the method comprising administering migalastat to a patient in need thereof, wherein the patient has an α-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of: I242F, G334E, N34D and p.V254del.
2. The method of claim 1 , wherein the mutation is selected from the group consisting of G334E, N34D and p.V254del.
3. The method of claim 1 , wherein the mutation is I242F.
4. The method of claim 1 , wherein the mutation is G334E.
5. The method of claim 1 , wherein the mutation is N34D.
6. The method of claim 1 , wherein the mutation is p.V254del.
7. The method of claim 1 , wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.
8. The method of claim 7 , wherein the mutation is selected from the group consisting of G334E, N34D and p.V254del.
9. The method of claim 7 , wherein the mutation is I242F.
10. The method of claim 7 , wherein the mutation is G334E.
11. The method of claim 7 , wherein the mutation is N34D.
12. The method of claim 7 , wherein the mutation is p.V254del.
13. A method of treating Fabry disease, the method comprising administering migalastat to a patient in need thereof, wherein the patient has an α-galactosidase A protein comprising a HEK assay amenable mutation N215I.
14. The method of claim 13 , wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.